Investors

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
05/17/18GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress
SOUTH SAN FRANCISCO, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that data supporting its voxelotor program in sickle cell disease (SCD) will be presented during the 23rd European Hematology Association (EHA) Congress in Stockholm, taking place June 14-17, 2018. A total of five abstracts have been accepted for poster presentation including 24-week data on patients treated with the 900 mg dose of voxelotor in Part B of the HOPE-KID... 
Printer Friendly Version
05/07/18GBT Reports Recent Business Progress and First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2018. "During the first quarter of 2018, we continued to remain focused on the clinical development of voxelotor for the treatment of sickle cell disease, and we have invested further in our commercial infrastructure with the appointment of David L. Johnson as chief commercial offi... 
Printer Friendly Version
05/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 14,250 shares of the Company’s common stock with a per share exercise price of $45.20, the closing trading price on the grant date, and restricted stock units for an aggregate of 9,400 shares of the Company’s common stock.... 
Printer Friendly Version
04/03/18GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover,... 
Printer Friendly Version
04/03/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 2, 2018, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 750 shares of the Company’s common stock with a per share exercise price of $44.20, the closing trading price on the grant date, and a restricted stock unit award for 500 shares of the Company’s common stock. All of the above-describe... 
Printer Friendly Version
03/15/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors granted David L. Johnson an option to purchase 55,000 shares of the Company’s common stock with a per share exercise price of $54.05, the closing trading price on the grant date, and a restricted stock unit award for 35,000 shares of the Company’s common stock. All of the above-d... 
Printer Friendly Version
03/12/18Global Blood Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 600,000 shares of GBT’s common stock. Inc... 
Printer Friendly Version
03/08/18Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $54.00 per share.  The gross proceeds from this offering are ex... 
Printer Friendly Version
03/08/18Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq:GBT), a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced a registered offering of 3,500,000 shares of its common stock.  The offering is expected to close on or about March 13, 2018, subject to customary closing conditions.  In additio... 
Printer Friendly Version
03/06/18GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer
Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the “Company”) (Nasdaq:GBT) today announced the appointment of David L. Johnson as chief commercial officer, effective March 12, 2018. Mr. Johnson joins GBT from Gilead Sciences, Inc., where he was vice president, sales and marketing, L... 
Printer Friendly Version
03/05/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ:GBT) today announced that on March 1, 2018, the compensation committee of the Company’s board of directors granted four new employees options to purchase an aggregate of 7,500 shares of the Company’s common stock with a per share exercise price of $58.80, the closing trading price on the grant date, and restricted stock units for an aggregate of 4,950 shares of the Compa... 
Printer Friendly Version
03/05/18GBT Announces Participation at Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in March 2018: Cowen and Company 38th Annual Health Care Conference in Boston on March 12 at 11:20 a.m. Eastern Time (ET); 28th Annual Oppenheimer Healthcare Conference in New York City on March 20 at 10:55 a.m. ET; and 17th Annual Needham Healthcare Conference in New York City on March 27 at... 
Printer Friendly Version
02/27/18GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2017. "We continue to build positive momentum toward bringing voxelotor, the first and only sickle cell disease (SCD) treatment to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration, to the SCD community,” said Ted W. Love, M.D., presi... 
Printer Friendly Version
02/07/18GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 9:00 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About Global Blood Therapeutics GBT is a clinical-stage biopharmaceutical compa... 
Printer Friendly Version
01/09/18GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously... 
Printer Friendly Version
01/03/18GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time. The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, deve... 
Printer Friendly Version